title: Disease modification: promising targets and impediments to success.
abstract: Osteoarthritis (OA) is a significant and growing concern to a large segment of the population. Effective treatments for slowing or stopping the progression of the disease are not available despite a great deal of investment-backed effort on the part of academia, government, and the pharmaceutical industry. Target selection has been problematic. Progress may also have been hindered to some extent by the prevalent cartilage-centric view of OA. Significant clinical development challenges remain for novel therapeutics in this area. This review elaborates on the challenges of disease-modifying OA drug development and points out specific therapeutic intervention strategies recently tried or currently being pursued.
authors: Orthopaedic & Regenerative Medicine Research, Genzyme, A Sanofi Company, Framingham, MA 01701, USA. gloria.matthews@sanofi.com
authors: Gloria L
authors: GL
authors: Matthews
mesh_terms: D000818:Animals; D018501:Antirheumatic Agents / Q000627:therapeutic use; D002358:Cartilage, Articular / Q000473:pathology* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D019468:Disease Management; D004195:Disease Models, Animal; D055808:Drug Discovery; D006801:Humans; D007596:Joints / Q000473:pathology* / Q000503:physiopathology; D010003:Osteoarthritis / Q000473:pathology* / Q000503:physiopathology / Q000628:therapy*; D011788:Quality of Life; D020127:Recovery of Function
chemical_list: D018501:Antirheumatic Agents